How the body metabolizes next-generation anti-androgen agents affects their anti-tumor activity in the treatment of prostate cancer.
As molecular testing becomes the standard of care for many cancers, nurse navigators have an important role to play ensuring molecular testing of suitable patients, providing patient education, and managing of patient expectations.
Precision Medicine Improves Pancreatic Cancer Treatment
Analysis & Perspective on Practical and Ethical Use and Interpretation of Whole Genome Sequencing Data During Clinical TrialsApril 20, 2017
Despite the value of genomic sequence information, nurses need to be aware of the limitations of this information and ethical concerns regarding sharing it with patients.
Steroid produced by human fetal liver reduces testosterone levels, holding potential as treatment for advanced prostate cancer.
Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.
Genome editing technology illustrates progression of normal blood cells to leukemia.
The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.
The majority of consumers do not change their health-related behaviors in the wake of personal genomic test results.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
The recurrence score assay stratifies early stage, estrogen receptor-positive breast cancer by recurrence risk. This study assessed how clinicians use the recurrence score to recommend adjuvant systemic therapy or patients' experiences with testing decision-making.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
DNA methylation profiling identified the primary cancer in cases of cancer of unknown primary, informing tumor-type specific treatment that improved overall survival in these patients.
Applying evolutionary theory improves the accuracy of predicting in which patients Barrett's esophagus will progress to esophageal adenocarcinoma.
Precision medicine based on genetic makeup of tumors is leading to anticancer treatments that target specific patients; however, racial and ethnic minorities are underrepresented in genomic samples, resulting in less benefit from advances in cancer care for these patients.
The 70-gene signature test, in combination with standard clinical-pathologic criteria, may help clinicians decide whether patients with early stage breast cancer who are at high clinical risk require adjuvant chemotherapy.
ESR1 mutations are more frequent in patients with estrogen receptor (ER)-positive metastatic breast cancer that are treated with aromatase inhibitors, according to recent study data.
The National Cancer Moonshot needs to target proteins that are driving cancer rather than focusing only on genomics, a new paper suggests.
The geometric shape of the outside edge of a cancerous tumor plays a significant role in activating tumor-seeding cells that lead to metastasis.
Disparities in the gut microbiome between healthy people and women with estrogen-driven breast cancer may indicate possible biomarkers based on the microbiome that could help to mitigate the risk of certain cancers.
A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.
[Biomarkers in Cancer] This research examines the emerging role of genomic rearrangements in breast cancer, with a particular focus on fusion genes, and explores the therapeutic value of such rearrangements and their significance as predictive and prognostic biomarkers.
Despite improvements in genomic sequencing technologies, a significant number of medically important genes are within genomic regions in which sequencing lacks the technical accuracy to generate reliable reads.
Participation in human research may improve with full disclosure and increased transparency of the risks of participating in publicly shared, big-data research projects.
Detailed new information about diffuse glioma has come from an international collaborative study, raising hopes for improved clinical outcomes from a better understanding of the disease.
Patients younger than 50 years with NSCLC were more likely to have a targetable genomic alteration for which therapies exist.
Genetic analyses and other tests performed by both researchers and physicians can be significantly skewed when normal cells, especially immune cells, are intermixed with cancerous cells in a tissue sample.
An international team mined RNA sequences to identify non-protein-coding segments whose expression is linked to 13 different types of cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|